CSIMarket
 


Abbvie inc   (ABBV)
Other Ticker:  
 
 

ABBV's Free Cash Flow Growth by Quarter and Year

Abbvie Inc 's Free Cash Flow results by quarter and year




ABBV Free Cash Flow (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 4,753.00 7,428.00 5,075.00 4,854.00
III Quarter September 7,574.00 7,602.00 7,935.00 5,830.00
II Quarter June 6,319.00 5,005.00 4,890.00 3,089.00
I Quarter March 4,193.00 4,908.00 4,877.00 3,815.00
FY   22,839.00 24,943.00 22,777.00 17,588.00



ABBV Free Cash Flow fourth quarter 2023 Y/Y Growth Comment
Abbvie Inc reported fall in Free Cash Flow in the fourth quarter 2023 by -36.01% to $ 4,753.00 millions, from the same quarter in 2022.
The drop in the fourth quarter 2023 Abbvie Inc 's Free Cash Flow compares unfavorably to the Company's average Free Cash Flow increase of 16.27%.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 22 other companies have achieved higher Free Cash Flow growth. While Abbvie Inc ' s Free Cash Flow drop of -36.01% ranks overall at the positon no. 1102 in the fourth quarter 2023.




ABBV Free Cash Flow ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December -36.01 % 46.36 % 4.55 % 48.21 %
III Quarter September -0.37 % -4.2 % 36.11 % 27.99 %
II Quarter June 26.25 % 2.35 % 58.3 % 24.71 %
I Quarter March -14.57 % 0.64 % 27.84 % 26.45 %
FY   -8.44 % 9.51 % 29.5 % 32 %

Financial Statements
Abbvie Inc 's fourth quarter 2023 Free Cash Flow $ 4,753.00 millions ABBV's Income Statement
Abbvie Inc 's fourth quarter 2022 Free Cash Flow $ 7,428.00 millions Quarterly ABBV's Income Statement
New: More ABBV's historic Free Cash Flow Growth >>


ABBV Free Cash Flow (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -37.25 % -2.29 % -36.04 % -16.74 %
III Quarter September 19.86 % 51.89 % 62.27 % 88.73 %
II Quarter June 50.7 % 1.98 % 0.27 % -19.03 %
I Quarter March -43.55 % -3.29 % 0.47 % 16.49 %
FY (Year on Year)   -8.44 % 9.51 % 29.5 % 32 %




Free Cash Flow fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #23
Healthcare Sector #94
Overall #1102

Free Cash Flow Y/Y Growth Statistics
High Average Low
222.85 % 16.27 % -85.06 %
(Sep 30 2015)   (Dec. 31. 2012)
Free Cash Flow fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #23
Healthcare Sector #94
Overall #1102
Free Cash Flow Y/Y Growth Statistics
High Average Low
222.85 % 16.27 % -85.06 %
(Sep 30 2015)   (Dec. 31. 2012)

Free Cash Flow by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Abbvie Inc 's Q/Q Free Cash Flow Growth


Free Cash Flow Q/Q Growth Statistics
High Average Low
223.41 % 19.21 % -80.85 %
(June 30. 2014)  


ABBV's IV. Quarter Q/Q Free Cash Flow Comment
In the IV. Quarter 2023 Abbvie Inc realized fall in Free Cash Flow sequentially by -37.25% to $ 4,753.00 millions, from $ 7,574.00 millions declared a quarter before.

This is not huge problem, as IV. Quarter Free Cash Flow always tend to slow in the IV. Quarter Austin Lee, Major Pharmaceutical Preparations industry veteran located in New York wrote.

Within Major Pharmaceutical Preparations industry 16 other companies have achieved higher Free Cash Flow quarter on quarter growth. While Abbvie Inc 's Free Cash Flow growth quarter on quarter, overall rank is 882.


Free Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #17
Healthcare Sector #75
Overall #882
Free Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #17
Healthcare Sector #75
Overall #882
Free Cash Flow Q/Q Growth Statistics
High Average Low
223.41 % 19.21 % -80.85 %
(June 30. 2014)  


ABBV's IV. Quarter Q/Q Free Cash Flow Comment
In the IV. Quarter 2023 Abbvie Inc reported fall in Free Cash Flow from the previous quarter by -37.25% to $ 4,753.00 millions, from $ 7,574.00 millions declared in the previous quarter.

As we evaluate current slump at the IV. Quarter, we suppose to presume, that usually IV. Quarter Free Cash Flow emerge sluggish in contrast to the quarter before, Austin Lee, Major Pharmaceutical Preparations industry veteran located in New York added.

Within Major Pharmaceutical Preparations industry 16 other companies have achieved higher Free Cash Flow quarter on quarter growth. While Abbvie Inc 's Free Cash Flow growth quarter on quarter, overall rank is 882.


Abbvie Inc 's 12 Months Free Cash Flow Growth Year on Year


Free Cash Flow TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Free Cash Flow 12 Months Ending $ 23,616.00 $ 26,299.00 $ 26,285.00 $ 24,936.00 $ 25,638.00
Y / Y Free Cash Flow Growth (TTM) -7.89 % 13.07 % 11.23 % 5.8 % 8.8 %
Year on Year Free Cash Flow Growth Overall Ranking # 680 # 1452 # 712 # 715 # 550
Seqeuential Free Cash Flow Change (TTM) -10.2 % 0.05 % 5.41 % -2.74 % 10.23 %
Seq. Free Cash Flow Growth (TTM) Overall Ranking # 664 # 1465 # 1371 # 1049 # 946




Cumulative Free Cash Flow growth Comment
For the 12 months ended Dec 31 2023 Abbvie Inc reported a decrease in Free Cash Flow by -7.89% year on year, to $23,616 millions, compare to the 13.07% growth at Sep 30 2023.

In the Healthcare sector 48 other companies have achieved higher trailing twelve month Free Cash Flow growth. While Total ranking has impoved so far to 680, from total ranking in previous quarter at 1452.

Free Cash Flow TTM Q/Q Growth Statistics
High Average Low
93.87 %
7.41 %
-62.2 %
 

Free Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 9
Healthcare Sector # 49
Overall # 680

Free Cash Flow TTM Y/Y Growth Statistics
High Average Low
93.87 %
7.41 %
-62.2 %
 


Free Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 48
S&P 500 # 664
Cumulative Free Cash Flow growth Comment
For the 12 months ended Dec 31 2023 Abbvie Inc reported a decrease in Free Cash Flow by -7.89% year on year, to $23,616 millions, compare to the 13.07% growth at Sep 30 2023.

In the Healthcare sector 48 other companies have achieved higher trailing twelve month Free Cash Flow growth. While Total ranking has impoved so far to 680, from total ranking in previous quarter at 1452.

Free Cash Flow TTM Q/Q Growth Statistics
High Average Low
93.87 %
7.41 %
-62.2 %
 


Free Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 9
Healthcare Sector # 49
Overall # 680

Free Cash Flow TTM Y/Y Growth Statistics
High Average Low
93.87 %
7.41 %
-62.2 %
 


Free Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 48
S&P 500 # 664




Other Free Cash Flow Growth
Major Pharmaceutical Preparations Industry Free Cash Flow Growth Trends and Statistics
Healthcare Sector Free Cash Flow Growth Statistics
Free Cash Flow Growth Trends for overall market
ABBV's Free Cash Flow Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Free Cash Flow Growth
Lowest Ranking Free Cash Flow Growth
Free Cash Flow Growth for ABBV's Competitors
Free Cash Flow Growth for Abbvie Inc 's Suppliers
Free Cash Flow Growth for ABBV's Customers

You may also want to know
ABBV's Annual Growth Rates ABBV's Profitability Ratios ABBV's Asset Turnover Ratio ABBV's Dividend Growth
ABBV's Roe ABBV's Valuation Ratios ABBV's Financial Strength Ratios ABBV's Dividend Payout Ratio
ABBV's Roa ABBV's Inventory Turnover Ratio ABBV's Growth Rates ABBV's Dividend Comparisons



Companies with similar Free Cash Flow decrease for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Free Cash Flow for the quarter ending Dec 31 2023
Sanofi-2.55%$ -2.546 millions
Inmode Ltd -2.62%$ -2.617 millions
Charles River Laboratories International inc -5.88%$ -5.884 millions
Mettler toledo International Inc -7.29%$ -7.291 millions
Envista Holdings Corporation-7.52%$ -7.525 millions
Bio rad Laboratories Inc -10.37%$ -10.366 millions
Inspire Medical Systems inc -10.39%$ -10.390 millions
Insulet Corporation-10.85%$ -10.848 millions
Laboratory Corporation Of America Holdings-11.32%$ -11.322 millions
Hologic Inc-13.18%$ -13.181 millions
Neurocrine Biosciences Inc -13.64%$ -13.636 millions
Gilead Sciences Inc -15.50%$ -15.504 millions
Bausch Health Companies Inc -17.89%$ -17.895 millions
Koru Medical Systems Inc-17.93%$ -17.932 millions
Progyny Inc -26.90%$ -26.900 millions
Ufp Technologies Inc -29.00%$ -28.997 millions
Enhabit Inc -29.27%$ -29.268 millions
Integra Lifesciences Holdings Corp-31.15%$ -31.153 millions
Cryoport inc -32.07%$ -32.074 millions
Qiagen N v -35.76%$ -35.764 millions
Abbvie inc -36.01%$ -36.012 millions
Regeneron Pharmaceuticals Inc -36.64%$ -36.642 millions
Pfizer Inc-38.94%$ -38.942 millions
Axonics Inc -39.81%$ -39.805 millions
Warby Parker Inc -42.68%$ -42.678 millions
Catalent Inc -47.66%$ -47.664 millions
Intuitive Surgical Inc -47.86%$ -47.865 millions
Incyte Corporation-47.92%$ -47.921 millions
Jazz Pharmaceuticals Plc-51.07%$ -51.066 millions
Edwards Lifesciences Corporation-51.70%$ -51.697 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com